| . | Never (n = 617) . | Past (n = 380) . | Current (n = 282) . | P Value . |
|---|---|---|---|---|
| Age (y) | 62.1 ± 8.0 | 67.4 ± 6.2 | 64.0 ± 6.8 | <.001 |
| BMI (kg/m2) | 25.9 ± 4.5 | 26.0 ± 4.2 | 25.3 ± 4.0 | .084 |
| Fractures (%) | ||||
| VFA | 32 (5.2) | 30 (7.9) | 6 (2.1) | .005 |
| All fragility | 94 (15.2) | 89 (23.4) | 39 (13.8) | .001 |
| Major osteoporotic | 69 (11.2) | 58 (15.3) | 17 (6.0) | .001 |
| Calcium intake | ||||
| Diet (mg) | 954 ± 524 | 982 ± 506 | 1038 ± 571 | .102 |
| Supplements (%) | 215 (34.9) | 212 (55.8) | 105 (37.2) | <.001 |
| Plasma 25-hydroxyvitamin D (nmol/liter) | 51.1 ± 22.5 | 55.7 ± 23.1 | 56.6 ± 24.7 | .002 |
| FRAX , 10-y risk | 11.2 ± 7.1 | 13.4 ± 7.5 | 10.5 ± 5.6 | <.001 |
| . | Never (n = 617) . | Past (n = 380) . | Current (n = 282) . | P Value . |
|---|---|---|---|---|
| Age (y) | 62.1 ± 8.0 | 67.4 ± 6.2 | 64.0 ± 6.8 | <.001 |
| BMI (kg/m2) | 25.9 ± 4.5 | 26.0 ± 4.2 | 25.3 ± 4.0 | .084 |
| Fractures (%) | ||||
| VFA | 32 (5.2) | 30 (7.9) | 6 (2.1) | .005 |
| All fragility | 94 (15.2) | 89 (23.4) | 39 (13.8) | .001 |
| Major osteoporotic | 69 (11.2) | 58 (15.3) | 17 (6.0) | .001 |
| Calcium intake | ||||
| Diet (mg) | 954 ± 524 | 982 ± 506 | 1038 ± 571 | .102 |
| Supplements (%) | 215 (34.9) | 212 (55.8) | 105 (37.2) | <.001 |
| Plasma 25-hydroxyvitamin D (nmol/liter) | 51.1 ± 22.5 | 55.7 ± 23.1 | 56.6 ± 24.7 | .002 |
| FRAX , 10-y risk | 11.2 ± 7.1 | 13.4 ± 7.5 | 10.5 ± 5.6 | <.001 |
Results are expressed as number of participants (percentage) or as average ± standard deviation. Between groups analysis was performed by χ2 or analysis of variance.
| . | Never (n = 617) . | Past (n = 380) . | Current (n = 282) . | P Value . |
|---|---|---|---|---|
| Age (y) | 62.1 ± 8.0 | 67.4 ± 6.2 | 64.0 ± 6.8 | <.001 |
| BMI (kg/m2) | 25.9 ± 4.5 | 26.0 ± 4.2 | 25.3 ± 4.0 | .084 |
| Fractures (%) | ||||
| VFA | 32 (5.2) | 30 (7.9) | 6 (2.1) | .005 |
| All fragility | 94 (15.2) | 89 (23.4) | 39 (13.8) | .001 |
| Major osteoporotic | 69 (11.2) | 58 (15.3) | 17 (6.0) | .001 |
| Calcium intake | ||||
| Diet (mg) | 954 ± 524 | 982 ± 506 | 1038 ± 571 | .102 |
| Supplements (%) | 215 (34.9) | 212 (55.8) | 105 (37.2) | <.001 |
| Plasma 25-hydroxyvitamin D (nmol/liter) | 51.1 ± 22.5 | 55.7 ± 23.1 | 56.6 ± 24.7 | .002 |
| FRAX , 10-y risk | 11.2 ± 7.1 | 13.4 ± 7.5 | 10.5 ± 5.6 | <.001 |
| . | Never (n = 617) . | Past (n = 380) . | Current (n = 282) . | P Value . |
|---|---|---|---|---|
| Age (y) | 62.1 ± 8.0 | 67.4 ± 6.2 | 64.0 ± 6.8 | <.001 |
| BMI (kg/m2) | 25.9 ± 4.5 | 26.0 ± 4.2 | 25.3 ± 4.0 | .084 |
| Fractures (%) | ||||
| VFA | 32 (5.2) | 30 (7.9) | 6 (2.1) | .005 |
| All fragility | 94 (15.2) | 89 (23.4) | 39 (13.8) | .001 |
| Major osteoporotic | 69 (11.2) | 58 (15.3) | 17 (6.0) | .001 |
| Calcium intake | ||||
| Diet (mg) | 954 ± 524 | 982 ± 506 | 1038 ± 571 | .102 |
| Supplements (%) | 215 (34.9) | 212 (55.8) | 105 (37.2) | <.001 |
| Plasma 25-hydroxyvitamin D (nmol/liter) | 51.1 ± 22.5 | 55.7 ± 23.1 | 56.6 ± 24.7 | .002 |
| FRAX , 10-y risk | 11.2 ± 7.1 | 13.4 ± 7.5 | 10.5 ± 5.6 | <.001 |
Results are expressed as number of participants (percentage) or as average ± standard deviation. Between groups analysis was performed by χ2 or analysis of variance.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
